Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 2Phase 3 2Phase 1 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1

Conditions

Precancerous Conditions 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Sulindac × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00118365 2015-01-22

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

National Cancer Institute (NCI)

Phase 3 Completed
375 enrolled 27 charts
Other neoplasm

Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡